Filtered By:
Condition: Heart Attack
Management: Marketing

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 31 results found since Jan 2013.

Diet Beverages Linked To Increased Stroke Risk & Heart Attacks
This study, as well as other research on the connection between diet beverages and vascular disease, is observational and cannot show cause and effect. That’s a major limitation, researchers say, as it’s impossible to determine whether the association is due to a specific artificial sweetener, a type of beverage or another hidden health issue. “Postmenopausal women tend to have higher risk for vascular disease because they are lacking the protective effects of natural hormones,” North Carolina cardiologist Dr. Kevin Campbell said, which could contribute to increased risk for heart disease and stroke...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - February 14, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News CNN Heart Attack Stroke Source Type: news

Diet Drinks Linked To Increased Stroke Risk & Heart Attacks
This study, as well as other research on the connection between diet beverages and vascular disease, is observational and cannot show cause and effect. That’s a major limitation, researchers say, as it’s impossible to determine whether the association is due to a specific artificial sweetener, a type of beverage or another hidden health issue. “Postmenopausal women tend to have higher risk for vascular disease because they are lacking the protective effects of natural hormones,” North Carolina cardiologist Dr. Kevin Campbell said, which could contribute to increased risk for heart disease and stroke...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - February 14, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News CNN Heart Attack Stroke Source Type: news

Omega-3 no protection against heart attack or strokes, say scientists
Supplements do not offer cardiovascular benefits, researchers conclude from trials involving 112,000 peopleThe widespread belief that taking omega-3 capsules will help protect you from a heart attack, stroke or early death is wrong, according to a large and comprehensive review of the evidence.Thousands of people take omega-3 supplements regularly and for years. The belief that it protects the heart has spread – and is promoted in the marketing of the supplements – because the results from early trials suggested the capsules had cardiovascular benefits.Continue reading...
Source: Guardian Unlimited Science - July 17, 2018 Category: Science Authors: Sarah Boseley Health editor Tags: Health Medical research Food & drink Heart attack Stroke Science Life and style Society Source Type: news

New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profile backed by ove...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Rivaroxaban for Preventing Atherothrombotic Events in People with Acute Coronary Syndrome and Elevated Cardiac Biomarkers: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Abstract As part of its Single Technology Appraisal process, the National Institute for Health and Care Excellence (NICE) invited the company that manufactures rivaroxaban (Xarelto, Bayer) to submit evidence of the clinical and cost effectiveness of rivaroxaban for the prevention of adverse outcomes in patients after the acute management of acute coronary syndrome (ACS). The School of Health and Related Research Technology Appraisal Group at the University of Sheffield was commissioned to act as the independent Evidence Review Group (ERG). The ERG produced a critical review of the evidence for the clinical and cos...
Source: PharmacoEconomics - December 21, 2015 Category: Health Management Source Type: research

Testosterone Drugs May Be Overused, FDA Warns
WASHINGTON (AP) — The Food and Drug Administration is warning doctors against over-prescribing testosterone-boosting drugs for men, saying the popular treatments have not been established as safe or effective for common age-related issues like low libido and fatigue. The agency says drugmakers must clearly state in their labeling and promotions that the drugs, currently taken by millions of U.S. men, are only approved to treat low testosterone levels caused by disease or injury, not normal aging. Additionally, the FDA cautioned that the drugs may increase the risk of heart attack, stroke and other cardiovascular problem...
Source: Science - The Huffington Post - March 3, 2015 Category: Science Source Type: news

Making Sense of Nutraceuticals in China
The Chinese nutraceutical market is considered the third largest in the world after the US and Japan, or the fourth largest if Europe is counted as a single market.Despite strong fundamentals and high rates of annual growth, though, the Chinese market remains some way from realizing its true potential. Its evolution is muddied by ambiguities around what nutraceuticals actually are and how they should be managed.The result has been polarization between over-zealous regulation of so-called health foods, and a grey market where products have skirted approval procedures through questionable positioning or by exploiting alterna...
Source: EyeForPharma - February 10, 2017 Category: Pharmaceuticals Authors: Marc Yates Source Type: news

Hookah smoking raises cardiovascular risk comparable to traditional cigarette smoking, study finds
This study is believed to be the first to investigate the effects of hookah smoking on stiffening of the arteries. Studies have shown that as cigarette use continues to decline, hookah smoking is rising, especially among youth and particularly among college students.“We know that flavored tobacco products are frequently the first kind of tobacco product used by youth,” Rezk-Hanna said. “One of the major issues with hookah is the fact that the tobacco is flavored with fruit, candy and alcohol flavors, making hookah the most popular flavored tobacco produc t among this audience.”According to the Food and Drug Admini...
Source: UCLA Newsroom: Health Sciences - August 2, 2018 Category: Universities & Medical Training Source Type: news

In Brief: Tegaserod (Zelnorm) Returns
Date: May 6, 2019 Issue #:  1571Summary:  Tegaserod maleate(Zelnorm), a 5-HT4 receptor partial agonist that increases gastrointestinal (GI) motility, was approved by the FDA in 2002 for short-term treatment of irritable bowel syndrome with constipation (IBS-C) in women and in 2004 for treatment of chronic idiopathic constipation (CIC) in adults<65 years old.In 2007, the manufacturer (Novartis) complied with an FDA request to stop marketing the drug based on an unpublished retrospective analysis of clinical trials in IBS-C and other GI motility disorders that showed a higher rate of ischemic ...
Source: The Medical Letter - April 26, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Constipation irritable bowel syndrome Motegrity prucalopride Resotran Tegaserod Zelnorm Source Type: research

Any defence of sugar is pure confection | Aseem Malhotra
More and more people are challenging the food industry's PR machine. The evidence shows that sugar, not fat, is the enemyThe public health minister, Anna Soubry, has commented that the poor are more likely to be obese. It is well known that social status is linked to health, but her comments were also motivated by a mentality that victimises the most vulnerable. She should really be directing her criticism at the food industry. There is no doubt that an oversupply of cheap junk food fuelled by unregulated and irresponsible marketing limits our ability to make healthy choices. But there is an equally important question that...
Source: Guardian Unlimited Science - January 24, 2013 Category: Science Authors: Aseem Malhotra Tags: Comment Food & drink industry Obesity Health guardian.co.uk Health policy Society UK news Life and style Business Science Comment is free Source Type: news

FDA approves alogliptin for type 2 diabetes as three separate preparations
Source: FDA Area: News The FDA has approved alogliptin for the treatment of type 2 diabetes as three separate preparations: alogliptin monotherapy; alogliptin in combination with metformin; and alogliptin in combination with pioglitazone.   Alogliptin stimulates insulin release following meals and was shown to be safe and effective as monotherapy in 14 clinical trials involving approximately 8,500 patients with type 2 diabetes.  Alogliptin monotherapy reduced glycosylated haemoglobin (HBA1c) by 0.4 to 0.6% compared to placebo following 26 weeks of treatment.   The FDA has requested additional data ...
Source: NeLM - News - January 28, 2013 Category: Drugs & Pharmacology Source Type: news

Families face battle with GSK over dangerous diabetes drug
Exclusive: Pharmaceutical giant resists claims despite settlement with victims in USThousands of families in the UK could be deprived of compensation for the death or harm of a relative caused by the diabetes drug Avandia, even though the British maker has agreed to pay billions of dollars to settle similar claims in the US.The licence for Avandia was revoked in Europe, in September 2010, because of evidence that it could cause heart failure and heart attacks. The drug can still be prescribed in the US, but not to patients at risk of heart problems.A scientist with the Food and Drug Administration estimated that Avandia co...
Source: Guardian Unlimited Science - January 29, 2013 Category: Science Authors: Sarah Boseley Tags: The Guardian United States World news Pharmaceuticals industry Medical research Legal aid Law UK news Diabetes GlaxoSmithKline Business Source Type: news

FDA accepts review of long-delayed Merck blood clot drug
July 24 - Merck & Co. on Wednesday said U.S. regulators had accepted its marketing application for the blood clot drug vorapaxar, aimed at preventing heart attacks and strokes in patients who have already had a heart attack but who have no history of stroke.
Source: Reuters: Health - July 24, 2013 Category: Consumer Health News Tags: healthNews Source Type: news